<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020397</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068403</org_study_id>
    <secondary_id>NCI-01-C-0032</secondary_id>
    <secondary_id>NCI-2390</secondary_id>
    <nct_id>NCT00020397</nct_id>
    <nct_alias>NCT00006491</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma</brief_title>
  <official_title>Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating&#xD;
      patients who have refractory metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether an immunologic response can be obtained after administration of ESO-1&#xD;
           peptide vaccine comprising class I , II, or both peptides in HLA-A*201 or HLA-DPB1*04&#xD;
           positive patients with refractory metastatic melanoma expressing ESO-1.&#xD;
&#xD;
        -  Determine the toxicity of this vaccine in these patients.&#xD;
&#xD;
        -  Determine whether prior immunization with this vaccine results in increased clinical&#xD;
           responsiveness in patients treated with interleukin-2.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 3 groups according to HLA type.&#xD;
&#xD;
        -  Group 1 (HLA-A*201 and HLA-DPB1*04 positive): Patients receive ESO-1 peptide vaccine&#xD;
           comprising class I (ESO-1:157-165 [165V]) and class II (ESO-1:161-180) peptides&#xD;
           subcutaneously once every 3 weeks for 4 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Group 2 (HLA-A*201 positive and HLA-DPB1*04 negative):Patients receive ESO-1 peptide&#xD;
           vaccine as in group I comprising class I peptide only.&#xD;
&#xD;
        -  Group 3 (HLA-A*201 negative and HLA-DPB1*04 positive):Patients receive ESO-1 peptide&#xD;
           vaccine as in group I comprising class II peptide only.&#xD;
&#xD;
      Patients who develop disease progression discontinue vaccinations and receive high-dose&#xD;
      interleukin (IL-2) IV over 15 minutes every 8 hours for up to 4 days (maximum of 12 doses).&#xD;
      Treatment with IL-2 repeats every 10-14 days for 4 courses in the absence of disease&#xD;
      progression (after at least 2 courses) or unacceptable toxicity.&#xD;
&#xD;
      Patients who have stable disease or a mixed or partial response to vaccination or IL-2&#xD;
      therapy may be eligible for additional vaccine therapy. Patients who have a complete response&#xD;
      to vaccine therapy are eligible for 1 additional treatment.&#xD;
&#xD;
      Patients are followed at 3 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45-90 patients (15-30 per treatment group) will be accrued for&#xD;
      this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1 peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic melanoma that expresses ESO-1 antigen&#xD;
&#xD;
          -  Must have progressed during prior standard treatment&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  HLA-A*201 or HLA-DPB1*04 positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT and SGPT less than 3 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL (3.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac ischemia*&#xD;
&#xD;
          -  No myocardial infarction*&#xD;
&#xD;
          -  No cardiac arrhythmias* NOTE: *For interleukin-2 (IL-2) administration&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease (for IL-2 administration)&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No active primary or secondary immunodeficiency&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infections&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other active major medical illness (for IL-2 administration)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior ESO-1 immunization&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Recovered from any prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent systemic steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Recovered from any prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since any prior systemic therapy for cancer&#xD;
&#xD;
          -  No other concurrent systemic therapy for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004 Nov-Dec;27(6):472-7.</citation>
    <PMID>15534491</PMID>
  </results_reference>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

